Get the Immunohistochemistry PD-L1 SP142 Test for only $288 USD (regularly $376) across USA. This advanced cancer biomarker test helps determine immunotherapy eligibility for lung cancer
Get the Immunohistochemistry ATRX Test for only $88 USD (regular $140) across USA. Essential for brain tumor diagnosis Immunohistochemistry ATRX Test Original price was: $140.Current price is: $88.
Get comprehensive Immunohistochemistry SOX11 testing for cancer diagnosis and prognosis at only $88 USD. Essential for lymphoma detection Immunohistochemistry SOX11 Test Original price was: $112.Current price is: $88.
Sale!

Immunohistochemistry PD-L1 SP142 Test

Original price was: $376.Current price is: $288.

-23%

The Immunohistochemistry PD-L1 SP142 Test is a cutting-edge diagnostic tool that measures PD-L1 protein expression levels in tumor tissue samples. This specialized test plays a crucial role in determining patient eligibility for immunotherapy treatments, particularly immune checkpoint inhibitors. By detecting PD-L1 expression, oncologists can identify patients most likely to benefit from targeted immunotherapies that help the immune system recognize and attack cancer cells. The test is essential for patients with non-small cell lung cancer, triple-negative breast cancer, and other malignancies where immunotherapy may be effective. Results provide valuable insights for personalized treatment planning and improved clinical outcomes. The test costs $288 USD with our current discount, down from the regular price of $376 USD.

Trusted Testing. Expert Care. Guaranteed Privacy.

  • Accredited and Trusted
  • Expert Scientists, Advanced Technology
  • Data Privacy Guaranteed
Guaranteed Safe Checkout

Immunohistochemistry PD-L1 SP142 Test

Understanding the PD-L1 SP142 Test

The Immunohistochemistry PD-L1 SP142 Test represents a breakthrough in precision oncology, offering critical insights into cancer treatment options. This advanced diagnostic procedure detects the presence and expression levels of programmed death-ligand 1 (PD-L1) protein on tumor cells using the highly specific SP142 antibody. The test serves as a vital biomarker for predicting response to immunotherapy, revolutionizing how oncologists approach cancer treatment strategies.

What Does the PD-L1 SP142 Test Measure?

This sophisticated test specifically measures PD-L1 protein expression in tumor tissue samples through immunohistochemistry methodology. The SP142 antibody clone provides exceptional specificity in detecting PD-L1 expression patterns, including:

  • Tumor cell PD-L1 expression levels
  • Immune cell PD-L1 expression in the tumor microenvironment
  • Combined positive score (CPS) calculations
  • Tumor proportion score (TPS) assessments

Who Should Consider This Test?

The PD-L1 SP142 Test is particularly valuable for patients diagnosed with specific cancer types where immunotherapy has demonstrated significant efficacy:

  • Patients with non-small cell lung cancer (NSCLC) considering immunotherapy options
  • Individuals diagnosed with triple-negative breast cancer
  • Patients with urothelial carcinoma or bladder cancer
  • Those with head and neck squamous cell carcinoma
  • Patients experiencing treatment resistance to conventional therapies
  • Individuals seeking personalized cancer treatment approaches

Key Benefits of PD-L1 SP142 Testing

Undergoing PD-L1 SP142 testing provides numerous advantages for cancer patients and their healthcare teams:

  • Treatment Guidance: Determines eligibility for immune checkpoint inhibitors
  • Personalized Therapy: Enables tailored treatment plans based on biomarker status
  • Improved Outcomes: Identifies patients most likely to respond to immunotherapy
  • Cost-Effective Care: Avoids unnecessary treatment expenses for non-responders
  • Enhanced Survival: Contributes to better overall survival rates in responsive patients
  • Comprehensive Assessment: Provides detailed tumor microenvironment analysis

Understanding Your Test Results

Your PD-L1 SP142 test results will provide critical information for treatment decisions:

  • Positive Result: Indicates significant PD-L1 expression, suggesting potential response to immunotherapy
  • Negative Result: Shows minimal PD-L1 expression, indicating alternative treatment approaches may be more appropriate
  • Combined Positive Score (CPS): Measures both tumor and immune cell PD-L1 expression
  • Tumor Proportion Score (TPS): Specifically evaluates tumor cell PD-L1 expression

Your oncologist will interpret these results in the context of your specific cancer type, stage, and overall health status to develop the most effective treatment strategy.

Test Pricing Information

Price Type Amount (USD)
Discount Price $288
Regular Price $376

Nationwide Testing Availability

We proudly offer the Immunohistochemistry PD-L1 SP142 Test across our extensive network of testing facilities throughout the United States. Our state-of-the-art laboratories serve patients in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and countless other cities nationwide.

Ready to Take the Next Step?

Don’t leave your cancer treatment decisions to chance. The PD-L1 SP142 Test provides the critical biomarker information needed to make informed treatment choices. Our experienced team is ready to assist you with scheduling, sample collection, and result interpretation.

Call us today at +1(267) 388-9828 to book your Immunohistochemistry PD-L1 SP142 Test and take control of your cancer treatment journey.

Test Specifications

  • Turnaround Time: Block: 5 days | Tissue Biopsy: 5 days | Tissue Large Complex: 7 days
  • Sample Requirements: Submit tumor tissue in 10% Formal-saline OR Formalin fixed paraffin embedded block
  • Shipping Instructions: Ship at room temperature with required documentation
  • Required Documentation: Histopathology report, biopsy site information, and clinical history
SKU: 1397 Category:

Related products